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Effects of early intracoronary streptokinase on 
infarct size estimated from cumulative enzyme 
release and on enzyme release rate: A 
randomized trial of 533 patients with acute 
myocardial infarction* 
The effects of early intracoronary streptokinase (SK) on enzymatic infarct size and rate of 
enzyme release were studied in a randomized multicenter trial. A total of 533 patients with acute 
myocardial infarction (AMI) were allocated to either the SK treatment group (n = 269) or the 
conventional (control) treatment group (n = 264). Enzymatic infarct size was represented by the 
cumulative quantfty of a-hydroxybutyrate dehydrogenase (HBDH) released by the heart per liter 
of plasma in the first 72 hours. Rate of enzyme release was represented by the ratio of HBDH 
quantities released in 24 hours and 72 hours. On an “intention to treat” basis, the SK group had 
a smaller (by 30%; p = 0.0001) median enzymatic infarct size and a higher (by 35%; p = 0.0001) 
median rate of enzyme release than the control group. Limitation of infarct size was less 
apparent in patients treated with intracoronary SK only (25%) than in patients treated with 
intravenous plus intracoronary SK (34%). Compared to the control Qroup, the enzyme release 
rate in patients treated with intracoronary SK only was slightly less (34%) than that in patients 
treated wfth intravenous plus intracoronary SK (36%). Patients with a patent infarct-related 
coronary artery at acute angiography had a median infarct size which was 55% (p = 0.0001) 
smaller than the median infarct size of the control group, and the median rate of enzyme release 
was 36% (p = 0.001) higher than the median release rate of the control group. Patients with 
successful recanalization during intracoronary SK infusion had a median infarct size which was 
31% (p = 0.002) smaller than the median infarct size of the control group and a median rate of 
enzyme release which was 42% (p = 0.0001) higher than the median release rate of the control 
group. Patients with persistent coronary occlusion in spite of thrombolytic therapy had a median 
infarct size which was 11% (NS) higher than the median infarct size of the control group, 
although the median rate of enzyme release was still 23% (p = 0.02) higher than the median 
release rate of the control group. It is concluded that thrombolysis in the early phase of AMI 
limits infarct size and that intracoronary SK treatment itself accelerates the process of enzyme 
release from infarcted myocardium, independent of the angiographic result. (AM HEART J 
1966;112:672.) 
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Both short- and long-term prognosis of patients who 
have had a myocardial infarction depends largely on 
“infarct size,” or rather on the remaining function- 
ing myocardial tissue. 1-4 Thus it is likely that limita- 
tion of “infarct size” will lead to a better prognosis of 
infarct patients. Early recanalization of the occluded 
coronary artery in patients with acute myocardial 
infarction (AMI) has been proposed as a method for 
myocardial salvage. 5. 6 We recently completed a 
study of 533 patients comparing early recanalization 
by intracoronary administration of streptokinase 
(SK) with conventional treatment. The results indi- 
cate that early recanalization does indeed limit 
“infarct size” (estimated from serial enzyme deter- 
minations), thereby preserving myocardial function 
(estimated by contrast angiography and radionu- 
elide angiography). Finally, the l-year survival rate 
in patients allocated to thrombolytic therapy was 
significantly improved compared to that of patients 
in the control group (91% vs 84%).7-g 
This report further details the effects of thrombo- 
lytic therapy on the estimated “infarct size” by 
calculation of total a-hydroxybutyrate dehydroge- 
nase (HBDH) enzyme release and the effects of 
treatment on the rate of enzyme release. Limitation 
of infarct size was only apparent in patients with a 
patent infarct-related artery after the intervention. 
However, in contrast with earlier reports,lO-l3 the rate 
of enzyme release appeared to be accelerated by 
thrombolytic therapy independent of the angio- 
graphic results. 
METHODS 
Patient selection. The study, sponsored by the Nether- 
lands Interuniversity Cardiology Institute, was initiated in 
one hospital in 1981 and later extended to five hospitals.7- 
‘.I1 All patients admitted to the participating coronary 
care units were eligible for the trial if severe chest pain 
lasting more than 20 minutes was accompanied by ST 
segment elevation of 0.2 mV or greater in one or more 
precordial leads and/or 0.1 mV or greater in one or more 
limb leads. In addition, patients were included who had 
0.2 mV ST segment depression in precordial leads indica- 
tive of posterior wall infarction. Patients up to the age of 
70 years were included if they were admitted to the 
coronary care unit within four hours after the onset of 
symptoms. Exclusion criteria were: previous treatment 
with SK, bypass surgery of the infarct-related vessel, 
recent trauma, traumatic resuscitation, gastrointestinal 
bleeding, gastric or duodenal ulcer, hematuria or cerebro- 
vascular accident within 3 months, pregnancy or menstru- 
ation, or inability to give informed consent. 
Eligible patients were registered by a telephone answer- 
ing service which then provided treatment allocation. 
After randomization, informed consent was requested 
from patients allocated to the group receiving thrombolyt- 
ic therapy only.‘” Prior to cardiac catheterization patients 
received nitroglycerin, lidocaine (2 mg/min), heparin 
(5000 U), acetylsalicylic acid (250 mg), and prednisolone 
(100 mg) intravenously. Coronary arteriography was per- 
formed with preformed catheters from the femoral 
approach. If the infarct-related artery appeared occluded, 
SK was administered intracoronarily at the rate of 4000 
U/min until all visible clots disappeared. Usually 250,000 
U was given. In patients with persistent occlusion, subsel- 
ective infusion or mechanical perforation of the thrombus 
was attempted on occasion, while percutaneous translumi- 
nal coronary angioplasty was performed in some of the 
patients with severe residual stenosis of the infarct- 
related coronary artery.” In order to reduce treatment 
delay, in patients admitted since January, 1984, 500,000 11 
of SK was administered intravenously, immediately after 
informed consent was obtained, as soon as possible, 
followed by intracoronary SK infusion during acute cardi- 
ac catheterization.: 
Measurement of serum enzyme activities. Samples of 
5 ml of venous blood were obtained at admission, directly 
after the SK infusion procedure (if allocated to study 
treatment), every 12 hours for the first 2 days, and daily 
for the following 3 days. The blood samples were allowed 
to clot, and the activities of HBDH in the serum were 
measured in the coronary care units of Rotterdam Tho- 
raxcenter, Maastricht St. Annadal Hospital, and the Uni- 
versity Hospital Leiden, and the activity of lactate dehy- 
drogenase (LDH) in the serum was measured in the 
Rotterdam Zuiderziekenhuis and the Amsterdam Free 
University Hospital. Because erythrocytes contain high 
activity levels of LDH-1 and LDH-2, hemolytic samples 
were discarded, and new samples were ordered. 
Activity levels are expressed in micromoles of a-ketobu- 
tyrate converted (HBDH) or micromoles of pyruvate 
converted (LHD) per minute or liter of serum at 37O C. 
The autoanalyzers which measured HBDH activities were 
calibrated daily such that the HBDH activity of a test 
serum (Autonorm H, batch 227, Nyegaard & Co, Oslo, 
Norway) equaled 430 U/L. So calibrated, the mean refer- 
ence value of HBDH activity in serum is X3 Ii/L. From the 
autoanalyzers, which measured LDH activities, the serum 
LDH activities were converted to HBDH activities via the 
following formulas: Amsterdam Free University Hospital 
HBDH = 1.106 X LDH + 16 (r = 0.96), and Rotterdam 
Zuiderziekenhuis HBDH = 0.473 x LDH - 5 (r = 0.99). 
These formulas were obtained after LDH and HBDH 
measurement of 10 dilutions of an infarct serum diluted 
with a pasteurized plasma protein solution (,Central Labo- 
ratory of the Netherlands Red Cross Blood Transfusion 
Service, Amsterdam, the Netherlands) spanning an LDH 
range of 0 to 2660 U/L. 
Calculation of cumulative HBDH release. Previously 
the two-compartment model was presented” with which 
the movements of liberated myocardiat proteins IO and 
from intravascular and extravascular spaces can be 
described. This model has now been verified for a great 
number of proteins, mostly enzymes. Briefly. this model 
October, ,986 
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Table I. Median values (M) and first and third quartiles (Ql,Q3) of calculated and estimated cumulative HBDH 
release of patients allocated to thrombolytic therapy and to conventional treatment (control subjects) groups 
Patients 
Streptokinase Control 
n M Q, Q3 n M Q, Q3 P* 
448 patients with HBDHQ72 calculated? 
4% patients with HBDHQ72 calculated 
(448) or estimated including 17 patients 
without AMI (Q72 = 40 U/L) and 30 
patients who died early (8 SK, 22 
control, Q72 = 6000 U/L) 1 
29 patients with Q?2 estimated by 
1.2 x 648 
9 patients with Q72 estimated from 
CK(MB) curves 
All 533 patients with Q72§ 
230 770 450 1230 218 1020 580 1630 0.0001 
248 770 410 1260 247 1100 580 1860 0.0001 
14 860 600 1500 15 1290 910 1850 0.0001 
7 400 200 500 2 - 1050 1250 0.0001 
269 760 400 1250 264 1140 630 1860 0.0001 
*Mann-Whitney test. 
fIndicated by HBDHQ72. 
IIndicated by HBDHQ72A. 
$Indicated by HBDHQ’IPB. 
AMI = acute myocardial infarction. 
enables the calculation of the total quantity of enzyme 
which has entered the plasma up to time t (Q[t]) per liter 
of plasma. If the release of enzymes into plasma starts at 
time t = 0, Q(t) equals the quantity of enzyme present in 1 
L of plasma (C,[t]) plus the quantity of enzyme present in 
the extravascular compartment per liter of plasma (C,[t]) 
plus the quantity of enzyme that has been eliminated from 
1 L of plasma up to time t. Cumulative release of enzyme 
per liter of plasma up to timet t, Q(t), is represented by: 
Q(t) = C’,(t) + C’,(t) + FCR/C’,(r)dr (equation l), in 
which FCR is the fractional citabolic rate constant, and 
C’,(t) and C’,(t) are the enzyme concentrations at time t 
in plasma and the extravascular space, respectively. The 
accents added to C’,(t) and C’,(t) in equation 1 indicate 
that enzyme concentrations are corrected for the normal 
steady-state concentration (C,), that is, C’,(t) = 
c,(t) - G. 
This implies that Q(t) does not include normal steady- 
state release of enzyme but only refers to the extra release 
of enzyme resulting from AMI. The term C’.(t) can be 




e(ERR,r). C’,,(T)dr (equation 2), in which 
TER and ERR represent the transcapillary escape rate 
constant and the extravascular return rate constant, 
respectively.1s With the use of fixed mean values for FCR, 
TER, and ERR being 0.015 hr-‘, 0.014 hr-I, and 0.018 hr-‘, 
respectively, Q(t) was calculated from serial determina- 
tions of serum HBDH activities and the normal steady- 
state HBDH activity C, = 83 U/L. The total HBDH 
activity ultimately released by the infarcted myocardium 
is represented by HBDHQ72 as at 72 hours after onset of 
chest pain enzyme release rate is almost (a-95 % ) complet- 
ed by then.18 
Calculation of HBDH release rate. As a measure of the 
rate with which enzymes are liberated from the myocardi- 
urn into the circulation, the ratio HBDHQ24/HBDHQ72 
is used, that is, the ratio of the quantities released in the 
first 24 hours and the first 72 hours. 
Statistical analysis. Differences between medians of 
two groups of data were tested with the Mann-Whitney 
rank-sum test. Differences with p values >0.05 (two- 
sided) were considered not significant. 
RESULTS 
Between June, 1981, and March, 1985, a total of 
533 patients were entered into the study. Two 
hundred sixty-four patients were allocated to the 
conventional treatment group and 269 patients to 
the thrombolytic therapy group. In spite of treat- 
ment allocation, no angiography was performed in 
35 patients7r8 In 111 of 136 patients catheterized 
without intravenous SK the infarct-related vessel 
was occluded (82 % ) and recanalization was achieved 
in 79% of these. After prior intravenous SK the 
infarct-related vessel was patent in 40 of 98 patients 
(41%). Ultimately the infarct-related artery was 
patent at admission or recanalized in 198 patients 
(85%). The median time between onset of symp- 
toms and angiographic documentation of a patent 
infarct-related vessel was 200 minutes. 
Of 533 patients included in the study, measure- 
ments of HBDH (or LDH) were complete in 448 
patients (84 % ). The measurements were incomplete 
in 85 patients. In order to verify whether the results 
Volume 112 
Number 4 Thrombolysis and infarct size in AM 675 
would be affected by missing data, HBDHQ72 was 
estimated from other data which were available for 
these 85 patients. Data were missing from 17 
patients who did not develop an infarct in spite of 
prolonged chest pain and significant ST segment 
elevation at admission. In these 17 patients creatine 
kinase (CK), CK-MB, HBDH, and other enzymes 
remained within reference ranges. Furthermore, 
data were necessarily incomplete in 30 patients who 
died early (within 72 hours) from large infarctions, 
characterized by pulmonary edema, cardiogenic 
shock, and a rapid rise of plasma enzymes to high 
levels. In the present analysis these patients were 
entered with values for HBDHQ72 which were 
arbitrarily set at 40 (for patients without infarct) 
and 6000 (for patients who died within 72 hours), 
respectively. The figures 40 and 6000 U/L corre- 
sponded to the lowest and the highest values of the 
448 calculated infarct sizes. In 29 patients inade- 
quate blood sampling prevented direct calculation 
of infarct size; however, HBDHQ72 could be approx- 
imated by multiplication of calculated HBDHQ48 
by a factor of 1.2. This factor 1.2 was chosen because 
it was the value of the HBDHQ72/HBDHQ48 ratio 
in 218 control patients. Although in the patients 
allocated to the thrombolytic therapy group the 
mean ratio of HBDHQ72/HBDHQ48 was about 1.1, 
the factor 1.2 was used in all 29 patients in whom 
HBDHQ48 was present and HBDHQ72 was absent. 
Thus probably a small overestimation of infarct size 
was introduced in 14 patients allocated to the SK 
treatment group. In the nine patients in whom 
HBDHQ48 could not be calculated, HBDHQ72 was 
estimated via comparison of serum CK(MB) curves 
with serum CK(MB) curves of patients with calcu- 
lated HBDHQ72. 
The data presented in Table I show that the 
median infarct size estimated from HBDHQ72 was 
25% lower in patients allocated to thrombolysis 
than in control patients. This difference in 
HBDHQ72 was hardly affected by the addition of 
the estimated data to the actual measurements: in 
fact, inclusion of estimated infarct sizes 
(HBDHQ72A and HBDHQ72B) increased these dif- 
ferences to 30% and 33 % , respectively. These dif- 
ferences were similar among the five participating 
hospitals. Further analysis is based on both actual 
HBDH measurements (448 patients; HBDHQ72) 
and on data including patients without infarction 
and those who died early (495 patients; 
HBDHQ72A). Although much attention has been 
paid to the standardization of serum enzyme deter- 
minations, it appears that median HBDHQ72 values 
INFARCI SIZE LIMITATION PER PARTICIPAT:M’ CFNTEH 
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Fig. 1. Median value of enzymatic infarct size 
(HBDHQ’72A) in patients allocated to thrombolytic ther- 
apy (SK) is plotted against HBDHQ72A in patients 
allocated to conventional treatment (C) per participating 
center. Although an interdepartment variation is obvious, 
each center shows an almost identical result in terms of 
infarct size limitations of about 30 ‘Y 
varied per center. This was true for both patient 
groups (SK and control). Fig. 1 shows the median 
HBDHQ72A values in both patient groups per 
center. Although an interdepartment variation is 
obvious, each center shows an almost identical lower 
(by 30%) HBDHQ72 value in the SK group of 
patients than in control patients. 
Table II shows the medians and quartiles of 
calculated HBDH release (HBDHQ) after 24, 48, 
and 72 hours from the onset of infarction in patients 
in the control and SK groups. Evidently, after 24 
hours median HBDHQ values in both patient 
groups are almost identical, while cumulative 
HBDH release increases less during the following 2 
days in the SK group than in the control group. At 
72 hours from the onset of infarction, the median 
HBDHQ72 value of the SK group is 25% less than 
that of the control group (p = 0.0001). The differ- 
ence in the time course of HBDH release between 
the two groups of patients is the result of a faster 
release of HBDH in the SK group than in the 
control group, as is reflected by the median 
HBDHQ24MBDHQ72 which is 0.65 and 0.48 in the 
SK and control group, respectively (p = 0.0001). 
Table III shows that median HBDHQ72A values 
differ by 25% in favor of SK in the first 277 patients 
and by 34% in favor of SK in patients pretreated 
with intravenous SK. The HBDH release rate was 
34% and 38 % higher in the SK group than in the 
control group for intracoronary SK and intravenous 
plus intracoronary SK treatment, respectively. 
Fig. 2 shows the median values as well as the first 
and third quartile values of HBDHQ72A and ratio 
HBDHQ24/HBDHQ72 in patients in the control 
October, 1986 
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Table II. Median values (M) and first and third quartiles (Ql,Q3) of cumulative quantities of HBDH released per 
liter of plasma after 24, 48, 72, and 96 hours in patients allocated to thrombolytic therapy and to conventional 
treatment (control subjects) groups 
Streptokinase Controls 
n M QI Q3 n M Q, Q, P* 
HBDHQ24 252 460 260 780 236 490 300 730 NS 
HBDHQ48 245 680 420 1070 234 920 530 1390 0.003 
HBDHQ72 230 770 450 1230 218 1020 580 1630 0.0001 
HBDHQ96 187 780 450 1280 171 1050 620 1750 0.0006 
HBDHQ24/HBDHQ72 230 0.65 0.55 0.76 218 0.48 0.39 0.58 0.0001 
NS = not significant. 
*Mann-Whitney rank-sum test (two-sided). 
Table Ill. Median values (M) and first and third quartiles (Ql,Q3) of enzymatic infarct size (HBDHQ72A) and 
enzyme release rate (HBDHQ24/HBDHQ72) in patients allocated to thrombolytic therapy and to conventional 
treatment (control subjects)* 
Infarct size Streptokinase Control 
HBDHQ72A n M Q, Q3 n M &I Q3 Pi 
All patients 248 770 410 1260 247 1100 580 1860 0.0001 
Intracoronary SK 140 750 380 1220 137 1000 580 1700 0.001 
Intravenous + intracoronary SK 108 810 450 1320 110 1220 640 2010 0.001 
Enzyme release rate Streptokinase Control 
HBDHQ24/HBDHQ72 n M 8, Q3 n M QI Q3 Pf 
All patients 230 0.65 0.55 0.76 218 0.48 0.39 0.58 
Intracoronary SK 127 0.67 0.57 0.76 121 0.50 0.39 0.61 
Intravenous + intracoronary SK 103 0.65 0.53 0.76 97 0.47 0.40 0.54 
*Until 1984, SK was given intracoronarily only, and from January, 1984, on SK was given intravenously followed by intracoronarily. 




and SK groups. In addition, the SK group is subdi- 
vided into four groups of patients: those without 
catheterization (35 patients), 65 with a patent 
infarct-related coronary artery at angiography, 133 
patients with actual recanalization by thrombolytic 
therapy, and 36 patients in whom the artery 
remained occluded (Fig. 2). 
Median infarct sizes of the patients without acute 
coronary angiography (910 U/L), as well as those of 
the patients in whom the infarct-related artery 
remained occluded (1220 U/L), were not significant- 
ly different from those of control patients (1100 
U/L). In patients with recanalization during angiog- 
raphy median infarct size was 760 U/L, which is 
31% lower than in control patients @ = 0.0001). 
The smallest infarcts were observed in 65 patients 
who already had a patent infarct-related artery at 
first angiography (median 500 U/L). In Fig. 2 the 
values of the ratio HBDHQ24LHBDHQ72 are pre- 
sented, which are a measure of the rate of enzyme 
release. The control group and the patients in the 
SK group who did not undergo acute coronary 
angiography had a relatively low median ratio 
HBDHQ24/HBDHQ72 (0.48 and 0.55, respectively) 
compared to patients with patent infarct-related 
coronary arteries (0.66), those with recanalization 
during angiography (0.68), and those with persistent 
occlusion (0.59). 
In order to study whether the severity of the 
remaining stenosis of the infarct-related artery had 
any effect on infarct size or rate of enzyme release, 
patients were subdivided according to the visual 
interpretation of the degree of stenosis after recana- 
lization. The results in Fig. 2 show no effect of the 
degree of opening of the infarct-related artery on 
infarct size. 
Fig. 3 shows that in both anterior (including 
anteroseptal infarcts) and inferior (including poste- 
rior) infarcts cumulative HBDH release was lower 
and HBDH release rate was higher in patients 
allocated to SK treatment compared to control 
patients. When both groups are compared, median 
values of HBDHQ72A differ by 34 % (p = 0.007) and 
by 31% (p = 0.002) for patients with anterior and 
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Fig. 2. Median values of enzymatic infarct size 
(HBDHQ72A) and rate of enzyme release (HBDHQ24/ 
HBDHQ72) in patients allocated to streptokinase (SK) 
and control (C) treatment groups, (top), in four categories 
of patients allocated to SK treatment group (middle), and 
in four categories of patients with patency of recanalized 
infarct-related coronary artery (bottom). The number of 
data per bar is indicated in the bar, and the number of 
patients per group is indicated below the bar. Levels of 
first and third quartiles are indicated. Statistical signifi- 
cance of a difference between two medians is calculated by 
Mann-Whitney rank-sum test (two-sided). 
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Fig. 3. Median values of enzymatic infarct size 
(HBDHQ’ISA) and rate of enzyme release (HBDHQ24/ 
HBDHQ72) in patients having anterior infarction or 
inferior infarction allocated to streptokinse (SK) and 
control (C) treatment groups. The number of data per bar 
is indicated in the bar, and the number of patients per 
group is indicated below the bar. Levels of first and third 
quartiles are indicated. Statistical significance of a differ- 
ence between two medians is calculated by Mann-Whit- 
ney rank-sum test (two-sided). 
chest pain and per infarct size class per group are 
shown. This figure demonstrates that thrombolytic 
therapy is associated with both limitation of infarct 
size and an improved survival rate when compared 
to control patients. 
Of the 264 control patients and 269 patients 
allocated to the SK treatment group, angiographic 
data before discharge from the hospital were 
obtained from 125 and 129 patients with first AMI, 
respectively. Fig. 5 shows that in the SK group the 
median HBDHQ72 was 800 U/L, which was 33% 
lower Cp = 0.0001) than that in the control group 
(1190 U/L). Furthermore, in the SK group median 
inferior infarcts, respectively. Median values of the 
HBDHQ24/HBDHQ72 ratio differ by 31% 
(p = 0.0001) and 38% (p = 0.0001) for patients with 
anterior and inferior infarcts, respectively. 
From a total of 533 patients randomized in the 
study, 65 (12 % ) patients have died within 1 year 
after onset of chest pain: 23 patients allocated to 
thrombolytic therapy and 42 control patients 
03 = 0.01). In Fig. 4 the number of patients from 
both groups in four classes of infarct size 
(HBDHQ72A G 600 U/L, 601 to 1200 U/L, 1201 to 
1800 U/L, and >1800 U/L) and the number of 
patients who have died within 1 year after onset of 
676 van der Laarse et al. 
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Fig. 4. Mortality rates in four different classes of infarct 
size in patients allocated to thrombolytic therapy (SK) 
and in patients allocated to conventional treatment (C) 
groups. 
left ventricular ejection fraction at discharge was 
0.57, which was 14% higher (p = 0.0005) than that 
in the control group (0.50). 
DISCUSSION 
The aim of thrombolytic therapy is rapid restora- 
tion of blood flow to the jeopardized myocardium in 
order to preserve cellular integrity and function or, 
in other words, “limitation of infarct size.” Thus 
thrombolytic therapy must either prevent the 
infarction or lead to an infarct with a size smaller 
than would occur in the absence of thrombolysis- 
induced reperfusion of the infarct-related coronary 
artery. 
Indirectly, limitation of infarct size by early intra- 
coronary SK infusion has been demonstrated to 
occur since regional and global left ventricular func- 
tion as well as the mortality rate were markedly 
improved in treated patients compared to conven- 
tionally treated patients.7-s However, studies de- 
signed to investigate direct effects of thrombolytic 
therapy in terms of infarct size limitation are scarce. 
Therefore, in the study on thrombolytic therapy 
conducted by the Netherlands Interuniversity Car- 
diology Institute, measurement of enzymatic infarct 
size was incorporated. In 495 of 533 patients (93 % ) 
enrolled in the study quantitative information on 
infarct size (HBDHQ72A) was obtained. This study 
demonstrates that early thrombolysis does limit 
infarct size estimated by myocardial HBDH release. 
As expected, the smallest median HBDH infarct size 
was observed in patients with an open artery at 
angiography and, to a lesser extent, in patients with 
an occluded artery which later recanalized. Patients 
with a persistent occlusion in spite of thrombolytic 
therapy had the same infarct size as patients in the 
control group. 
IN PATIENTS WITH FIRST AM1 : 
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Fig. 5. Relation between left ventricular ejection frac- 
tion (LVEF) determined before discharge from coronary 
care unit and enzymatic infarct size (HBDHQ72A) in 254 
patients with first AM1 allocated to streptokinase (SK) or 
control (C) treatment group. Per treatment group median 
values and first and third quartiles are presented. Statis- 
tical significance of a difference between two medians is 
calculated by Mann-Whitney rank-sum test (two-sided). 
The method used to calculate infarct size in the 
present study is applicable to several cytoplasmic 
enzymes liberated from infarcted myocardium.‘s-22 
Based on the assumption that different cytoplasmic 
(iso) enzymes are liberated from necrotic myocytes 
simultaneously, the different serum (iso)enzyme 
curves can be fully described by differences in their 
concentrations in normal myocytes and differences 
in fractional catabolic rate. Calculation of cumula- 
tive released quantities of these (iso)enzymes results 
in identical overlapping curves when activities are 
expressed in gram equivalents of myocardium.21 
Thus the different cytoplasmic (iso)enzymes are 
released to the same extent percentagewise from 
the infarcted tissue. In infarcted animal hearts23-25 
and in infarcted human hearts26 the extent to which 
the infarcted myocardium looses its enzymes is 
approximately 80% to 85%. 
The two-compartment model employed enables 
calculation of the cumulative activity released from 
the infarcted myocardium into the plasma space for 
each cytoplasmic (iso)enzyme. The method has 
proved its value for assessing myocardial damage 
induced by surgical and cardioplegic procedures27-2s 
and for assessing the relationship between enzymat- 
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ic infarct size and the occurrence of pump failure, 
ECG changes, conduction and rhythm disturbances, 
global left ventricular function, wall motion abnor- 
malities, and l-year survival rate.‘? Shell et aL30 in 
1971, published a different method for calculating 
enzymatic infarct size, which has since then been 
used by a large number of investigators. This meth- 
od is confined to CK and CK-MB, and is based on a 
one-compartment model. As in the early reports 
they mention a recovery rate of 30% of the CK (or 
CK-MB) activity,3O and since 1975 only 15%,3l the 
cumulative CK(-MB) activity calculated on the 
basis of serial serum CK(-MB) activities has to be 
multiplied by l/O.3 (early) or by l/O.15 (since 1975) 
to obtain the activity of CK(-MB) released by the 
heart. The remaining part of the released CK(-MB) 
is degraded locally in the heart according to the 
authors.“2 The factor representing recovery of CK 
liberated by necrotic myocytes in the circulation 
appears to be sensitive to the occurrence of reperfu- 
sion of infarcted myocardium. Roberts and Ishika- 
wa33 showed that two different relationships exist 
between accumulated CK release expressed in CK 
gram-equivalents of infarcted myocardium and ana- 
tomic infarct size during unperfused infarction and 
during infarction followed by early reperfusion. 
From reperfused myocardium greater CK release 
per gram of anatomic infarct size has been observed 
than from unreperfused myocardium. 
Tamaki et al.,34 who also used the method of Shell 
et al.,3o observed that in patients with AM1 success- 
fully treated with intracoronary urokinase more 
CK-MB was released per equivalent infarct volume 
estimated by myocardial emission tomography with 
thallium-201 than in patients with AM1 with unsuc- 
cessful thrombolysis. The discrepancies mentioned 
by these authors may reflect different recovery 
fractions of the enzyme in both situations, since CK 
as well as CK-MB are relatively unstable (iso) 
enzymes compared to aspartate aminotransferase 
and LDH (see also reference 25). However, the 
infarct size calculated by the method of Shell et al.3o 
in patients with AM1 correlated well with anatomic 
infarct size in patients who died from AMI, left 
ventricular ejection fraction in patients with first 
AMI, 37 and long-term survival rates.‘-4*38 Erhardt3g 
reported that in 43 patients with AM1 the peak 
serum levels of LDH and heat-stable LDH (repre- 
senting the combined activities of LDH-1 and LDH- 
2) were well correlated (r = 0.73 and r = 0.79, 
respectively) with anatomic infarct size, measured at 
postmortem examination. Anderson et al.,13 who 
measured serial activities of several (iso)enzymes in 
serum, calculated the integrated concentrations of 
serum LDH and serum LDH-1, and did not find 
significant differences between the SK group and 
the control group. However, recalculation of 
released quantities of LDH and LDH-1, by means of 
the method used in the present study, yielded a 
smaller infarct size after thrombolysis of 20% and 
40% with LDH and with LDH-1, respectively. This 
is in agreement with the better left ventricular 
ejection fraction after thrombolysis reported by 
Anderson et a1.13 Enzyme release rates (Q24/Q72) 
were 0.49 and 0.77 measured with LDH and 0.46 and 
0.70 measured with LDH-1 for control and SK- 
treated patients, respectively, which are indeed sim- 
ilar to the results of the present study. 
Another advantage of calculation of infarct size 
from HBDH rather than from CK values is that 
HBDH-infarct size can be incorporated easily and 
routinely in trials on infarct size limitation as serum 
HBDH has to measured only twice a day during the 
first 2 days and once a day during the following 3 
days at low cost. No assumption regarding the 
HBDH release function (f[t]) is incorporated in the 
calculation. Thus factors which increase (e.g., SK) or 
decrease (e.g., beta blockers) the HBDH release rate 
do not influence any parameter involved in the 
calculation. The quantity of the release as well as the 
rate at which HBDH is released are the outcome of 
the calculation, and can be used in rapidly releasing 
infarcts (reperfusion) as well as in slowly releasing 
infarcts (unreperfused infarcts) (see also reference 
22). 
The enzymatic method for quantitating myocar- 
dial infarct size has one major drawback since 
patients must survive the first 3 days to enable 
calculation of cumulative enzyme release. In order to 
prevent bias resulting from the higher mortality rate 
among patients in the control group, we included the 
patients who died early from extensive infarctions 
giving those a large value for HBDHQ72. Since this 
value was chosen arbitrarily nonparametric statisti- 
cal tests were used. Similarly, patients without 
infarction were included with a low value for 
HBDHQ72 (40 U/L). 
Enzyme washout, as expressed as the HBDHQ24/ 
HBDHQ72 release ratio, was increased in all groups 
of patients after thrombolytic therapy. The latter 
finding is not completely understood. Shell et als4” 
demonstrated that reperfusion of the infarcted myo- 
cardium significantly augments the release rate of 
CK-MB, while Ong et al.” reported that in patients 
with AM1 not treated with thrombolytic agents a 
rapid release rate of CK-MB correlated with 
improvement of global left ventricular function and 
regional left ventricular wall motion. These reports 
suggest that a rapid enzyme release rate is a mani- 
festation of recanalization, either spontaneous or 
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induced by thrombolytic therapy. Accordingly sev- 
eral authors advocated the use of the time to peak 
CK (or CK-MB) as a noninvasive in vitro index to 
determine the success of reperfusion.‘O-l3 However, 
the present study indicates that one should be very 
cautious about interpreting a rapid enzyme release 
rate to be a manifestation of thrombolysis-induced 
recanalization, since the median rate of HBDH 
release in the patients with unsuccessful SK treat- 
ment (0.59) was significantly (p < 0.02) higher than 
that in conventionally treated (control) patients 
(0.48) (Fig. 2). One can speculate on other effects of 
SK in infarcted hearts besides its thrombolytic 
action. Fung and Rabkin,42 who subjected rabbit 
hearts to ischemia (low-flow perfusion) plus anoxia 
(perfusate equilibrated with 95% nitrogen + 5% 
carbon dioxide), found that continuous administra- 
tion of SK before reperfusion and during reperfu- 
sion resulted in a greater recovery of ventricular 
function than reperfusion alone. Puckett et al.43 
demonstrated a vasodilatory effect of SK in the 
nonischemic, isolated rat heart. Furthermore, these 
authors found less enzyme release during reperfu- 
sion of the globally ischemic isolated rat heart in the 
presence of SK compared to the control ischemic rat 
heart, suggesting that SK offers an overall protec- 
tive effect from the damage normally incurred dur- 
ing ischemia. 
The present study supports the concept that early 
thrombolysis will limit infarct size. In fact, the 
greatest limitation of infarct size determined from 
HBDH release was observed in patients treated 
within 2 hours (37%), whereas the effect of throm- 
bolytic therapy was smaller in those treated between 
2 and 4 hours (13 % ). The limitation of infarct size 
was definitely related to the results of reperfusion 
(Fig. 2) and to preservation of global and regional 
left ventricular function as well as to the survival 
rate.7-g Further studies should compare the relative 
value of various interventions to establish reperfu- 
sion, including intravenous SK, rt-PA or acetylated 
SK-plasminogen complex, intracoronary adminis- 
tration of these compounds, and immediate percuta- 
neous transluminal coronary angioplasty. Determi- 
nation of infarct size by means of the methods in the 
present study will aid in the comparison of such 
interventions in addition to measurement of left 
ventricular function and survival. 
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